D.A. Davidson & Co. Harmony Biosciences Holdings, Inc. Transaction History

D.A. Davidson & Co.

$12 Billion
Q3 2024

A detailed history of D.A. Davidson & Co. transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, D.A. Davidson & Co. holds 26,944 shares of HRMY stock, worth $917,712. This represents 0.01% of its overall portfolio holdings.

Number of Shares

26,944

Previous 27,037 0.34%

Holding current value

$917,712

Previous $815,000 32.02%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$30.0 - $39.95 $2,790 - $3,715	-93 Reduced 0.34%	26,944 $1.08 Million
Q1 2024 May 13, 2024	SELL	$29.93 - $35.06 $478 - $560	-16 Reduced 0.06%	27,037 $907,000
Q4 2023 Feb 09, 2024	SELL	$19.2 - $33.78 $36,019 - $63,371	-1,876 Reduced 6.48%	27,053 $873,000
Q3 2023 Nov 08, 2023	SELL	$31.89 - $39.03 $24,906 - $30,482	-781 Reduced 2.63%	28,929 $948,000
Q2 2023 Aug 10, 2023	SELL	$30.5 - $37.4 $20,252 - $24,833	-664 Reduced 2.19%	29,710 $1.05 Million
Q1 2023 Apr 25, 2023	SELL	$30.8 - $53.92 $40,532 - $70,958	-1,316 Reduced 4.15%	30,374 $991,000
Q4 2022 Feb 03, 2023	SELL	$45.4 - $60.91 $4,630 - $6,212	-102 Reduced 0.32%	31,690 $1.75 Million
Q3 2022 Nov 07, 2022	SELL	$42.06 - $55.45 $33,732 - $44,470	-802 Reduced 2.46%	31,792 $1.41 Million
Q2 2022 Jul 28, 2022	SELL	$33.54 - $52.15 $15,931 - $24,771	-475 Reduced 1.44%	32,594 $1.59 Million
Q1 2022 May 12, 2022	BUY	$33.14 - $51.13 $1.1 Million - $1.69 Million	33,069 New	33,069 $1.61 Million

Others Institutions Holding HRMY

# of Institutions

242

Shares Held

45.1M

Call Options Held

108K

Put Options Held

49.2K

View Full List

About Harmony Biosciences Holdings, Inc.

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.02B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

More about HRMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.

Account